Thyroid Gland Adenocarcinoma — Trials

Thyroid Gland Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

195 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 43
Recruiting: 17
Ph III recruiting: 4
Growth YoY: —
Industry share: 7%
Top sponsor: M.D. Anderson Cancer Center
Termination share: 25.6%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (13)

clinicaltrialsPublishedShowing 51–56 of 56 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00118248	Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer	completed	Phase 2	41	National Cancer Institute (NCI)NIH	1	Feb 15, 2017	clinicaltrials
NCT00559949	Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine	completed	Phase 2	39	National Cancer Institute (NCI)NIH	2	Jan 30, 2017	clinicaltrials